View this article at: http://www.jci.org/articles/view/60001?key=cc1ffb111d21a482e652
HEMATOLOGY: A stimulus package for cutaneous T cell lymphomas: mutations in the protein proIL-16
There are many types of non-Hodgkin lymphoma (NHL); together they account for approximately 4% of all cancer diagnoses. Cutaneous T cell lymphomas (CTCLs) are a diverse group of NHLs that affect the skin. The mechanisms underlying the development of these conditions are not well understood. A team of researchers led by William Cruikshank, at Boston University School of Medicine, Boston, has now shed some light on these mechanisms, generating data using cells from patients with CTCL that suggest that the growth of advanced CTCLs is facilitated, at least in part, by mutations in the protein proIL-16.
TITLE: Loss of nuclear proIL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma
William W. Cruikshank
Boston University School of Medicine, Boston, Massachusetts, USA.
Phone: 617-638-5295; Fax: 617-638-5227; E-mail: firstname.lastname@example.org.
View this article at: http://www.jci.org/articles/view/41769?key=80d76940a50cd248a8d1
HEMATOLOGY: Role for the protein HVEM in red blood cell production
The production of red blood cells (a process known as erythropoiesis) is tightly controlled. This is to ensure that there are sufficient red blood cells to deliver adequate amounts of oxygen to the tissues but not too many such that unwanted blood clots form in the blood vessels, an event that can cause heart attack and stroke. Therapeutics that stimula
|Contact: Karen Honey|
Journal of Clinical Investigation